Kambam J R, Perry S M, Entman S, Smith B E
Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232.
Am J Obstet Gynecol. 1988 Aug;159(2):309-11. doi: 10.1016/s0002-9378(88)80073-5.
Plasma cholinesterase activity levels were studied in 15 pregnant patients with preeclampsia before and after the administration of therapeutic doses of magnesium sulfate. Plasma cholinesterase activity was also studied in 15 healthy nonpregnant and 15 healthy pregnant women. The mean plasma cholinesterase activity level in pregnant patients with preeclampsia before and after the administration of magnesium sulfate was 179 +/- 26 and 176 +/- 39 units/ml, respectively. The healthy nonpregnant patients and healthy pregnant patients had a plasma cholinesterase activity level of 426 +/- 85 and 264 +/- 24 units/ml, respectively. Our data demonstrated that magnesium has no significant effect on plasma cholinesterase activity. Our data also confirm that there is a significant reduction in plasma cholinesterase activity in pregnant patients with preeclampsia compared with either healthy nonpregnant or healthy pregnant patients. We conclude that the low level of plasma cholinesterase activity is probably responsible for the prolonged action of succinylcholine in pregnant patients with preeclampsia receiving magnesium sulfate.
对15例先兆子痫孕妇在给予治疗剂量硫酸镁前后的血浆胆碱酯酶活性水平进行了研究。还对15名健康非孕妇和15名健康孕妇的血浆胆碱酯酶活性进行了研究。先兆子痫孕妇在给予硫酸镁前后的平均血浆胆碱酯酶活性水平分别为179±26和176±39单位/毫升。健康非孕妇和健康孕妇的血浆胆碱酯酶活性水平分别为426±85和264±24单位/毫升。我们的数据表明镁对血浆胆碱酯酶活性没有显著影响。我们的数据还证实，与健康非孕妇或健康孕妇相比，先兆子痫孕妇的血浆胆碱酯酶活性显著降低。我们得出结论，血浆胆碱酯酶活性水平低可能是接受硫酸镁的先兆子痫孕妇中琥珀酰胆碱作用延长的原因。
